Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in advanced pretreated BRAF V600 wild-type melanoma
2018-004003-39Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trametinib in melanoma (2 arms), sponsored by UZ Brussel. Primary endpoint: Objective response rate. Started Oct 2018; status: completed.
02
Drugs
trametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-004003-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004003-39.